Literature DB >> 4920573

Amantadine hydrochloride in the treatment of Parkinson's disease.

B S Gilligan, J Veale, J Wodak.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1970        PMID: 4920573     DOI: 10.5694/j.1326-5377.1970.tb50241.x

Source DB:  PubMed          Journal:  Med J Aust        ISSN: 0025-729X            Impact factor:   7.738


× No keyword cloud information.
  6 in total

Review 1.  Levodopa: a review of its pharmacological properties and therapeutic use with particular reference to Parkinsonism.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1971       Impact factor: 9.546

2.  On the effect of amantadine on monoamines and their metabolites in the brain and cerebrospinal fluid.

Authors:  U K Rinne; V Sonninen; M Hyyppä
Journal:  Experientia       Date:  1972-01-15

3.  Amantadine-HCl (Symmetrel) in the management of Parkinson's disease: a double-blind cross-over study.

Authors:  A Barbeau; H Mars; M I Botez; M Joubert
Journal:  Can Med Assoc J       Date:  1971-07-10       Impact factor: 8.262

Review 4.  Amantadine in Parkinson's disease.

Authors:  N Crosby; K H Deane; C E Clarke
Journal:  Cochrane Database Syst Rev       Date:  2003

5.  Palladium-catalyzed amination of dichloroquinolines with adamantane-containing amines.

Authors:  Anton S Abel; Alexei D Averin; Olga A Maloshitskaya; Evgenii N Savelyev; Boris S Orlinson; Ivan A Novakov; Irina P Beletskaya
Journal:  Molecules       Date:  2013-02-06       Impact factor: 4.411

6.  Mono- and Diamination of 4,6-Dichloropyrimidine, 2,6-Dichloropyrazine and 1,3-Dichloroisoquinoline with Adamantane-Containing Amines.

Authors:  Alisa D Kharlamova; Anton S Abel; Alexei D Averin; Olga A Maloshitskaya; Vitaly A Roznyatovskiy; Evgenii N Savelyev; Boris S Orlinson; Ivan A Novakov; Irina P Beletskaya
Journal:  Molecules       Date:  2021-03-29       Impact factor: 4.411

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.